| 60 | 1 | 13 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:观察替米沙坦联合左卡尼汀对腹膜透析(PD)患者的临床疗效,以指导临床用药。方法:选择我科2011年11月~2014年1月随访的80例慢性肾功能衰竭(CRF)接受PD的患者为研究对象,随机分为治疗组和对照组;两组均常规进行PD,治疗组给予左卡尼汀口服液10mL/次、3次/d,替米沙坦80mg/次、1次/d,对照组给予左卡尼汀口服液10mL/次、3次/d,两组均连续服用24周;观察两组治疗前后血清肌酐(SCr)、尿毒氮(BUN)水平,并计算残余肾功能(RRF),观察治疗前后日均尿量及血压变化。结果:治疗后,治疗组SCr、BUN降低大于对照组,RRF降低小于对照组(P<0.05);治疗后日尿量均减少,治疗组减少低于对照组(P<0.05);治疗后收缩压和舒张压均降低,治疗组降低优于对照组(P<0.05)。结论:替米沙坦联合左卡尼汀用于尿毒症PD患者,能够有效延缓RRF的丧失,延缓尿量减少,调节血压水平,进而缓解临床症状,提高患者生存质量。
Abstract：Objective:To observe the therapeutic effect of telmisartan in combined with L-carnitine on the peritoneal dialysis(PD)patients in order to guide the clinical medication.Methods:A total of 80 patients with chronic renal failure(CRF)who were admitted in our hospital from November,2011 to January,2014 for PD were included in the study and randomized into the treatment group and the control group.The patients in the two groups were routinely performed with PD.The patients in the treatment group were given L-carnitine oral liquid,10 mL/time,3times/d,and telmisartan,80 mg/time,1time/d.The patients in the control group were given L-carnitine oral liquid,10mL/time,3times a day.The patients in the two groups were treated for 24 weeks continuously.The serum SCr and BUN levels before and after treatment in the two groups were observed.Residual renal function(RRF)was calculated.The changes of daily average urine volume and blood pressure before and after treatment in the two groups were observed.Results:After treatment,the reduced degree of SCr and BUN in the treatment group was significantly greater than that in the control group,while the reduced degree of RRF was significantly less than that in the control group(P<0.05).After treatment,the daily urine volume was reduced,but the reduced degree in the treatment group was significantly less than that in the control group(P<0.05).After treatment,SBP and DBP were reduced,but the reduced degree in the treatment group was significantly superior to that in the control group(P<0.05).Conclusions:Telmisartan in combined with L-carnitine applied in PD patients can effectively delay the loss of RRF and the reduction of urine volume,and regulate the blood pressure in order to alleviate the clinical symptoms and improve the patients' living qualities.
1何平.黄芪注射液对血液透析患者残余肾功能的影响[J].河南医学研究,2015,24(11):45-46.
2 韦洮,王梅,燕宇,等.血液透析患者残余肾功能的变化及其影响因素[J].北京医学,2012,34(7):283-286.
3 漆映辉,曲晓璐,唐咏华,等.黄芪注射液对血液透析患者残余肾功能的影响--附60例报告[J].新医学,2013,44(2):105-107.
4 徐雪峰,张攀科.参芎葡萄糖注射液对血液透析患者残余肾功能保护的疗效观察[J].中医中药,2012,19(13):108-109.
5 李丽,郭晓娟.维持性血液透析患者残余肾功能与生活质量的相关性[J].中国老年学杂志,2013,33(5):1156-1157.
6 黎磊石,刘志红.中国肾脏病学[J].北京:人民军医出版社,2008:640.
7 丛军,高弼虎.维持性血液透析对尿毒症患者氧化应激及免疫功能的影响[J].中华实用诊断与治疗杂志,2013,27(3):209-211.
8 李攀,常风云.肾康注射液对尿毒症血液透析患者残余肾功能的影响[J].中国实验方剂学杂志,2015,21(9):200-203.
9 刘晓云.左卡尼汀联合百令胶囊对腹膜透析患者残余肾功能、微炎症状态及营养状况的影响[J].实用药物与临床,2014,17(7):860-864.
10 桂志红,王会玲,张金元.维持性腹膜透析患者营养不良-炎症复合体综合征的认识[J].中国中西医结合肾病杂志,2010,11(5):462-463.
11 何平,苏晓晓,李德天.左卡尼汀联合促红细胞生成素改善NHD患者贫血及营养状态的疗效[J].实用药物与临床,2013,16(5):397-398.
12 周祖莲,余荣杰,吴雄飞,等.肾脏病理结合肾功能显像评价慢性肾病残余肾功能的临床意义[J].检验医学与临床,2011,8(15):1819-1820,1822.
13 宋韶娜.黄芪合参麦注射液对维持性血液透析患者残余肾功能及低血压的影响[J].中国医学工程,2015,23(8):33-34.
14 郭皓.厄贝沙坦联合左卡尼汀治疗维持性血液透析患者心力衰竭的疗效观察[J].中国现代医生,2014,52(7):70-72.
15 官继超,王时敏,单娟萍.替米沙坦联合尿毒清对腹膜透析患者残余肾功能的影响[J].中国中西医结合肾病杂志,2013,14(11):993-995
16 唐雪敏,任伟,江洁龙,等.替米沙坦对腹膜透析患者残存肾功能及血指代谢的作用[J].安徽医科大学学报,2013,48(2):174-177
17童玉娜,龚蓉.腹膜透析治疗与残余肾功能保护的研究进展[J].临床荟萃,2014,29(4):465-468.
基本信息:
DOI：10.13210/j.cnki.jhmu.20160302.003
中图分类号:R692.5
引用信息:
[1]程锦绣,潘星,刘华,等.替米沙坦联合左卡尼汀治疗腹膜透析患者疗效分析[J].海南医学院学报,2016,22(13):1458-1460.DOI:10.13210/j.cnki.jhmu.20160302.003.
基金信息:
河北省科技攻关计划项目(1421136D)~~
2016-03-02
2016-03-02
2016-03-02